The U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) announced they would purchase an additional supply of the casirivimab and imdevimab antibody cocktail for use by non-hospitalized COVID-19 patients.
The US government has said it will provide these doses at no cost to patients, though healthcare facilities may charge fees related to administration.
U.S. Government Purchases $2.6 Billion COVID-19 Antibody ‘Cocktails’
Practice’s Bariatric Nonsurgical Visits Up With Telehealth During Pandemic
Follow-up visits increased for nonsurgical providers; however, new patient and follow-up surgical visits did decrease
DKA Common in Blacks With T1DM and Confirmed COVID-19
Non-Hispanic Blacks with T1DM and COVID-19 have nearly fourfold increased odds of presenting with diabetic ketoacidosis
Negative COVID-19 Test to Be Required for People Flying to U.S.
Passengers without proof of a negative test will not be allowed to board flights to America
Women Must Get Abortion Pill in Person: U.S. Supreme Court
Similar in-person rules for other medications have been suspended during the pandemic
COVID-19 Vaccine Recommended for All Americans Over 65
Health officials also recommended COVID-19 vaccines be given to all adults with preexisting conditions
U.S. FDA Accepts for Priority Review the Biologics License Application for Investigational 15-valent Pneumococcal Vaccine
The U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older.
Merck announced the FDA set a Prescription Drug User Fee Act, or target action date, of July 18, 2021.
Composition of Gut Microbiome Altered in Patients With COVID-19
Several gut commensals with known immunomodulatory potential underrepresented in patients with COVID-19
Ischemic Heart, Hypertensive Disease Deaths Up During COVID-19
Second study shows reduction in cardiovascular diagnostic testing across the world during pandemic
Saliva, Nasopharyngeal Samples Equally Sensitive for SARS-CoV-2
Incremental cost of $8,093 per additional detection found with nasopharyngeal swab among individuals without previous SARS-CoV-2